Search research articles
Contact Us
Filters
Showing results (1-10 of 23) with videos related to
Page
of 3
Sort By:
Plos One
|
February 25, 2022
Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics
David R Nelson, Jacqueline Brown, Aki Morikawa, et al.
Nature Communications
|
April 22, 2015
Regulated delivery of molecular cargo to invasive tumour-derived microvesicles
James W Clancy, Alanna Sedgwick, Carine Rosse, et al.
Gynecologic Oncology
|
February 10, 2004
Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study
Franco M Muggia, John A Blessing, Michael Method, et al.
Future Oncology (London, England)
|
February 6, 2025
Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design
John Mascarenhas, Keri Maher, Raajit Rampal, et al.
Obstetrics and Gynecology
|
October 24, 2012
Management of endometrial precancers
Cornelia L Trimble, Michael Method, Mario Leitao, et al.
BMC Cancer
|
May 6, 2022
A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2- early breast cancer in the United States
Jacqueline Brown, Savannah Scardo, Michael Method, et al.
British Journal of Clinical Pharmacology
|
September 22, 2024
Exposure-response relationships of mirvetuximab soravtansine in patients with folate receptor-α-positive ovarian cancer: Justification of therapeutic dose regimen
Ya-Ping Tu, H Maxime Lagraauw, Michael Method, et al.
British Journal of Clinical Pharmacology
|
October 23, 2023
Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor-α positive ovarian cancer: The antibody-drug conjugate, payload and metabolite
Ya-Ping Tu, Eva Hanze, Fengying Zhu, et al.
Future Oncology (London, England)
|
May 25, 2022
A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer
Kristin M Sheffield, Jessica R Peachey, Michael Method, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
March 25, 2009
The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer
Patricia Braly, Christopher F Nicodemus, Christina Chu, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 23) with videos related to
Sort By:
Page
of 3
Plos One
|
February 25, 2022
Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics
David R Nelson, Jacqueline Brown, Aki Morikawa, et al.
Nature Communications
|
April 22, 2015
Regulated delivery of molecular cargo to invasive tumour-derived microvesicles
James W Clancy, Alanna Sedgwick, Carine Rosse, et al.
Gynecologic Oncology
|
February 10, 2004
Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study
Franco M Muggia, John A Blessing, Michael Method, et al.
Future Oncology (London, England)
|
February 6, 2025
Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design
John Mascarenhas, Keri Maher, Raajit Rampal, et al.
Obstetrics and Gynecology
|
October 24, 2012
Management of endometrial precancers
Cornelia L Trimble, Michael Method, Mario Leitao, et al.
BMC Cancer
|
May 6, 2022
A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2- early breast cancer in the United States
Jacqueline Brown, Savannah Scardo, Michael Method, et al.
British Journal of Clinical Pharmacology
|
September 22, 2024
Exposure-response relationships of mirvetuximab soravtansine in patients with folate receptor-α-positive ovarian cancer: Justification of therapeutic dose regimen
Ya-Ping Tu, H Maxime Lagraauw, Michael Method, et al.
British Journal of Clinical Pharmacology
|
October 23, 2023
Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor-α positive ovarian cancer: The antibody-drug conjugate, payload and metabolite
Ya-Ping Tu, Eva Hanze, Fengying Zhu, et al.
Future Oncology (London, England)
|
May 25, 2022
A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer
Kristin M Sheffield, Jessica R Peachey, Michael Method, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
March 25, 2009
The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer
Patricia Braly, Christopher F Nicodemus, Christina Chu, et al.
Page
of 3